Abstract:Histone deacetylase inhibitors (HDACi) are the most widely studied HIV latency-reversing agents (LRAs). The HDACi suberoylanilide hydroxamic acid (vorinostat [VOR]) has been employed in several clinical HIV latency reversal studies, as well as in vitro models of HIV latency, and has been shown to effectively induce HIV RNA and protein expression. Despite these findings, response to HDACi can vary, particularly with intermittent dosing, and information is lacking on the relationship between the host transcriptional response and HIV latency reversal. Here, we report on global gene expression responses to VOR and examine the longevity of the transcriptional response in various cellular models. We found that many genes are modulated at 6 h post-VOR treatment in HCT116, Jurkat, and primary resting CD4 T cells, yet return to baseline levels after an 18-h VOR-free period. With repeat exposure to VOR in resting CD4 T cells, we found similar and consistent transcriptional changes at 6 h following each serial treatment. In addition, serial exposure in HIV-infected suppressed donor CD4 T cells showed consistent transcriptional changes after each exposure to VOR. We identified five host genes that were strongly and consistently modulated following histone deacetylase (HDAC) inhibition; three (H1F0, IRGM, and WIPI49) were upregulated, and two (PHF15 and PRDM10) were downregulated. These genes demonstrated consistent modulation in peripheral blood mononuclear cell (PBMC) samples from HIV-positive (HIV + ) participants who received either single or multiple doses of 400 mg of VOR. Interestingly, the host transcriptional response did not predict induction of cell-associated HIV RNA, suggesting that other cellular factors play key roles in HIV latency reversal in vivo despite robust HDACi pharmacological activity. IMPORTANCE Histone deacetylase inhibitors are widely studied HIV latency-reversing agents (LRAs). VOR, an HDACi, induces histone acetylation and chromatin remodeling and modulates host and HIV gene expression. However, the relationship between these events is poorly defined, and clinical studies suggest diminished HIV reactivation in resting CD4 T cells with daily exposure to VOR. Our study provides evidence that VOR induces a consistent level of host cell gene transcription following intermittent exposure. In addition, in response to VOR exposure a gene signature that was conserved across single and serial exposures both in vitro and in vivo was identified, indicating that VOR can consistently and reproducibly modulate transcriptional host responses. However, as the HIV response to HDACi declines over time, other factors modulate viral reactivation in vivo despite robust HDAC activity. The identified host gene VOR biomarkers can be used for monitoring the pharmacodynamic activity of HDAC inhibitors.

Histonedeacetylase Inhibitor Oxamflatin Increase Hiv-1 Transcription by Inducing Histone Modification in Latently Infected Cells

Development of an Attenuated Tat Protein as a Highly-effective Agent to Specifically Activate HIV-1 Latency

Histone chaperone CAF-1 promotes HIV-1 latency by leading the formation of phase-separated suppressive nuclear bodies

Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui

Identify Potential Regulators in Hiv-1 Latency by Joint Microrna and Mrna Analysis

Histone deacetylase inhibitor MC1293 induces latent HIV-1 reactivation by histone modification in vitro latency cell lines.

Oxaliplatin Antagonizes HIV-1 Latency by Activating NF-κB Without Causing Global T Cell Activation.

Selective Histonedeacetylase Inhibitor M344 Intervenes in HIV-1 Latency Through Increasing Histone Acetylation and Activation of NF-kappaB.

Histone Deacetylase Inhibitor Scriptaid Reactivates Latent Hiv-1 Promoter By Inducing Histone Modification In In Vitro Latency Cell Lines

HIV-1 Reactivation Induced by Apicidin Involves Histone Modification in Latently Infected Cells.

Crosstalk Between Histone Modifications Indicates That Inhibition of Arginine Methyltransferase CARM1 Activity Reverses HIV Latency

A Novel Selective Histone Deacetylase I Inhibitor CC-4a Activates Latent HIV-1 Through NF-κB Pathway.

Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat

FBXO34 Promotes Latent HIV-1 Activation by Post-Transcriptional Modulation

HMBA Enhances Prostratin-Induced Activation of Latent HIV-1 Via Suppressing the Expression of Negative Feedback Regulator A20/TNFAIP3 in NF-κB Signaling

Wogonin Inhibits Latent HIV-1 Reactivation by Downregulating Histone Crotonylation

UHRF1 Suppresses HIV-1 Transcription and Promotes HIV-1 Latency by Competing with p-TEFb for Ubiquitination-Proteasomal Degradation of Tat

The KAT5-Acetyl-Histone4-Brd4 Axis Silences HIV-1 Transcription and Promotes Viral Latency

The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb

Resveratrol Promotes HIV-1 Tat Accumulation via AKT/FOXO1 Signal-ing Axis and Potentiates Vorinostat to Antagonize HIV-1 Latency

CBP/p300 lysine acetyltransferases inhibit HIV-1 expression in latently infected T-cells